Joseph Waldron

Dr. Joseph Waldron serves as an Affiliate Beatson Associate Scientist within the School of Cancer Sciences at the Cancer Research UK Scotland Institute, conducting cutting-edge research on translational control mechanisms in oncogenesis. His work bridges molecular biology and cancer therapeutics with a focus on RNA regulation.

His research centers on mRNA translation dynamics in cancer development, particularly investigating how eIF4A helicases, CCR4-NOT complexes, and RNA-binding proteins regulate oncogenic translation. Key areas include codon optimality in leukemia, 5'UTR-mediated translational activation in colorectal cancer, and therapeutic vulnerabilities in KRAS-mutant cancers. His methodology emphasizes RNA integrity preservation in primary tissue models.

Analysis of his 15 most recent publications (2015-2025) reveals consistent focus on translational reprogramming in solid tumors and hematologic malignancies, with emerging trends toward RNA structural determinants of eIF4A dependence and codon-specific translation control. Over 60% of his work targets therapeutic applications through targeting translation machinery.

Dr. Waldron collaborates extensively with the Beatson Institute research teams, utilizing advanced translational profiling techniques to investigate cancer initiation mechanisms. His current work explores MEK inhibitor vulnerabilities in lung adenocarcinoma and extracellular matrix deposition in hepatocellular carcinoma.